Company intelligence / Profile preview
Juneng Golden Key Pharmaceutical
- Ownership
- Private
- Development stage
- Other
Overview
Juneng Golden Key Pharmaceutical manufactures and markets proprietary Chinese patent medicines. The company was established with government investment in 2014, operates a modern production facility, and distributes its products domestically within China as well as to select Southeast Asian markets. There is no public clinical trial data; products are commercialized under China's regulatory framework for traditional medicines[1][2].
- Therapeutic areas
- Pulmonology
- Modalities
- Small moleculeHerbal medicine (Chinese patent medicine)
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Juneng Golden Key Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Juneng Golden Key Pharmaceutical.